Prolonged severe hypoglycemia, lasting 4–10 days, has been reported in neonates born to mothers receiving a sulfonylurea at the time of delivery and has been reported with the use of agents with a prolonged half-life. When initiating and increasing Glucotrol XL in patients who may be predisposed to hypoglycemia (e.g., the elderly, patients with renal impairment, patients on other anti-diabetic medications) start at 2.5 mg. Debilitated or malnourished patients, and those with adrenal, pituitary, or hepatic impairment are particularly susceptible to the hypoglycemic action of anti-diabetic medications.
Glipizide is an oral drug that is used for treating patients with type 2 diabetes. Therefore, Glucotrol XL should be discontinued at least two weeks before expected delivery The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20–25% in women with HbA1c >10. GLUCOTROL XL GENERIC NAME. Avoid use of Glucotrol XL in patients with G6PD deficiency. What oral medicines deal with type 2 diabetes?
When such drugs are administered to patients receiving Glucotrol XL, monitor the patients closely for worsening glycemic control. Increased frequency of monitoring may be required when Glucotrol XL is co-administered with these drugs.Monitor patients closely for hypoglycemia when Glucotrol XL is co-administered with miconazole. In a separate single dose study in 36 healthy subjects, four 2.5-mg Glucotrol XL tablets were bioequivalent to one 10-mg Glucotrol XL tablet.The mean volume of distribution was approximately 10 liters after single intravenous doses in patients with type 2 diabetes mellitus. Colesevelam can reduce the maximum plasma concentration and total exposure of glipizide when the two are coadministered Available data from a small number of published studies and postmarketing experience with Glucotrol XL use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal outcomes. When these medications are discontinued from patients receiving Glucotrol XL, monitor the patient closely for hypoglycemia.Alcohol, beta-blockers, clonidine, and reserpine may lead to either potentiation or weakening of the glucose-lowering effect. Glucotrol XL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Glucotrol XL is not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.Glucotrol XL should be administered orally with breakfast or the first main meal of the day.The recommended starting dose of Glucotrol XL is 5 mg once daily. If you are 65 or older, use Glucotrol XL (glipizide extended-release tablets) with care. Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death.Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents, including Glucotrol XL, can lead to hemolytic anemia. It is combined with diet and exercise. This is not a list of all drugs or health problems that interact with Glucotrol XL (glipizide extended-release tablets). No accumulation of drug was observed in patients with type 2 diabetes mellitus during chronic dosing with Glucotrol XL.Administration of Glucotrol XL with food has no effect on the 2 to 3 hour lag time in drug absorption. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The mean terminal elimination half-life of glipizide ranged from 2 to 5 hours after single or multiple doses in patients with type 2 diabetes mellitus.Studies characterizing the pharmacokinetics of glipizide in pediatric patients have not been performed.There were no differences in the pharmacokinetics of glipizide after single dose administration to older diabetic subjects compared to younger healthy subjects The pharmacokinetics of glipizide has not been evaluated in patients with varying degree of renal impairment. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported Monitor patients closely for hypoglycemia when Glucotrol XL is co-administered with fluconazole. Explain the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development to patients and responsible family members.